New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurological and inflammatory disorders

Bibliography

• Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007;76:481-511
   PubMed Web of Science ®Google Scholar
• Lugnier C. PDE inhibitors: a new approach to treat metabolic syndrome? Curr Opin Pharmacol 2011;11:698-706
   PubMed Web of Science ®Google Scholar
• Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006;109:366-98
   PubMed Web of Science ®Google Scholar
• Baeeri M, Foroumadi A, Motamedi M, et al. Safety and efficacy of new 3,6-diaryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine analogs as potential phosphodiesterase-4 inhibitors in NIH-3T3 mouse fibroblastic cells. Chem Biol Drug Des 2011;78:438-44
   PubMed Web of Science ®Google Scholar
• Rahimi R, Ghiasi S, Azimi H, et al. A review of the herbal phosphodiesterase inhibitors; future perspective of new drugs. Cytokine 2010;49:123-9
   PubMed Web of Science ®Google Scholar
• Dyke HJ, Montana JG. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 2002;11:1-13
   PubMed Web of Science ®Google Scholar
• Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 2003;63:2575-94
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Atashpour S, Pourkhalili N, et al. Comparative improvement in function of isolated rat Langerhans islets by various phosphodiesterase 3, 4 and 5 inhibitors. Asian J Anim Vet Adv 2011;6(12):1233-40
   Web of Science ®Google Scholar
• Ghiasi S, Abdollahi M. A review on the potential benefits of phosphodiesterase inhibitorsin various models of toxicities in animals. Asian J Anim Vet Adv 2012;7(3):210-24
   Web of Science ®Google Scholar
• Salari-Sharif P, Abdollahi M. Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review. Curr Pharm Des 2010;16:3661-7
   PubMed Web of Science ®Google Scholar
• Salari P, Abdollahi M. Phosphodiesterase inhibitors in inflammatory bowel disease. Expert Opin Investig Drugs 2012;21:261-4
   PubMed Web of Science ®Google Scholar
• Menniti FS, Faraci WS, Schmidt CJ. Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 2006;5:660-70
   PubMed Web of Science ®Google Scholar
• O'Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 2004;25:158-63
   PubMed Web of Science ®Google Scholar
• Birk S, Edvinsson L, Olesen J, Kruuse C. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries. Eur J Pharmacol 2004;489:93-100
   PubMed Web of Science ®Google Scholar
• Perez-Torres S, Cortes R, Tolnay M, et al. Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization. Exp Neurol 2003;182:322-34
   PubMed Web of Science ®Google Scholar
• Azadbar M, Ranjbar A, Hosseini-Tabatabaei A, et al. Interaction of phosphodiesterase 5 inhibitor with malathion on rat brain mitochondrial-bound hexokinase activity. Pestic Biochem Physiol 2009;95:121-5
   Web of Science ®Google Scholar
• Rezvanfar MA, Ranjbar A, Baeeri M, et al. Biochemical evidence on positive effects of rolipram a phosphodiesterase-4 inhibitor in malathion-induced toxic stress in rat blood and brain mitochondria. Pestic Biochem Physiol 2010;98:135-43
   Web of Science ®Google Scholar
• Giembycz MA, Corrigan CJ, Seybold J, et al. Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 1996;118:1945-58
   PubMed Web of Science ®Google Scholar
• Manning CD, Burman M, Christensen SB, et al. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 1999;128:1393-8
   PubMed Web of Science ®Google Scholar
• Abdollahi M, Chan TS, Subrahmanyam V, O'Brien PJ. Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin. Mol Cell Biochem 2003;252:205-11
   PubMed Web of Science ®Google Scholar
• Michaeli T, Bloom TJ, Martins T, et al. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J Biol Chem 1993;268:12925-32
   PubMed Web of Science ®Google Scholar
• Gardner C, Robas N, Cawkill D, Fidock M. Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun 2000;272:186-92
   PubMed Web of Science ®Google Scholar
• Sasaki T, Kotera J, Yuasa K, Omori K. Identification of human PDE7B, a cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 2000;271:575-83
   PubMed Web of Science ®Google Scholar
• Hetman JM, Soderling SH, Glavas NA, Beavo JA. Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. Proc Natl Acad Sci USA 2000;97:472-6
   PubMed Web of Science ®Google Scholar
• Glavas NA, Ostenson C, Schaefer JB, et al. T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc Natl Acad Sci USA 2001;98:6319-24
   PubMed Web of Science ®Google Scholar
• Han P, Zhu X, Michaeli T. Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J Biol Chem 1997;272:16152-7
   PubMed Web of Science ®Google Scholar
• Sasaki T, Kotera J, Omori K. Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation. Biochem J 2002;361:211-20
   PubMed Web of Science ®Google Scholar
• Bloom TJ, Beavo JA. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc Natl Acad Sci USA 1996;93:14188-92
   PubMed Web of Science ®Google Scholar
• Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006;58:488-520
   PubMed Web of Science ®Google Scholar
• Smith SJ, Brookes-Fazakerley S, Donnelly LE, et al. Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol 2003;284:L279-89
   PubMed Web of Science ®Google Scholar
• Morales-Garcia JA, Redondo M, Alonso-Gil S, et al. Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease. PLoS ONE 2011;6(2):e17240
   PubMed Web of Science ®Google Scholar
• Giembycz MA, Smith SJ. Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation? Curr Pharm Des 2006;12:3207-20
   PubMed Web of Science ®Google Scholar
• Soderling SH, Beavo JA. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 2000;12:174-9
   PubMed Web of Science ®Google Scholar
• Nakata A, Ogawa K, Sasaki T, et al. Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol 2002;128:460-6
   PubMed Web of Science ®Google Scholar
• Goto M, Kadoshima-Yamaoka K, Murakawa M, et al. Phosphodiesterase 7A inhibitor ASB16165 impairs proliferation of keratinocytes in vitro and in vivo. Eur J Pharmacol 2010;633:93-7
   PubMed Web of Science ®Google Scholar
• Zhang L, Murray F, Zahno A, et al. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2008;105:19532-7
   PubMed Web of Science ®Google Scholar
• Castro A, Jerez MJ, Gil C, Martinez A. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med Res Rev 2005;25:229-44
   PubMed Web of Science ®Google Scholar
• Wallis RM, Corbin JD, Francis SH, et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999;83(5A):3C-12C
   PubMed Web of Science ®Google Scholar
• Rena G, Begg F, Ross A, et al. Molecular cloning, genomic positioning, promoter identification, and characterization of the novel cyclic amp-specific phosphodiesterase PDE4A10. Mol Pharmacol 2001;59(5):996-1011
   PubMed Web of Science ®Google Scholar
• Dent G, White SR, Tenor H, et al. Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors. Pulm Pharmacol Ther 1998;11(1):47-56
   PubMed Web of Science ®Google Scholar
• Engels P, Fichtel K, Lfibbert H. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett 1994;350:291-5
   PubMed Web of Science ®Google Scholar
• Pelligrino DA, Wang Q. Cyclic nucleotide crosstalk and the regulation of cerebral vasodilation. Prog Neurobiol 1998;56:1-18
   PubMed Web of Science ®Google Scholar
• Antoni FA. Molecular diversity of cyclic AMP signalling. Front Neuroendocrinol 2000;21:103-32
   PubMed Web of Science ®Google Scholar
• Chin KV, Yang WL, Ravatn R, et al. Reinventing the wheel of cyclic AMP: novel mechanisms of cAMP signaling. Ann N Y Acad Sci 2002;968:49-64
   PubMed Web of Science ®Google Scholar
• Ledbetter JA, Parsons M, Martin PJ, et al. Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. J Immunol 1986;137:3299-305
   PubMed Web of Science ®Google Scholar
• Ottonello L, Morone MP, Dapino P, Dallegri F. Cyclic AMP-elevating agents down-regulate the oxidative burst induced by granulocyte-macrophage colony-stimulating factor (GM-CSF) in adherent neutrophils. Clin Exp Immunol 1995;101:502-6
   PubMed Web of Science ®Google Scholar
• Dumaz N, Marais R. Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. FEBS J 2005;272:3491-504
   PubMed Web of Science ®Google Scholar
• Stork PJ, Schmitt JM. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 2002;12:258-66
   PubMed Web of Science ®Google Scholar
• Taussig R, Gilman AG. Mammalian membrane-bound adenylyl cyclases. J Biol Chem 1995;270:1-4
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Sugahara S, Ikeda K, Shimizu Y. Pharmacological profile of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on acute and chronic inflammation models. Eur J Pharmacol 2006;550(1-3):166-72
   PubMed Web of Science ®Google Scholar
• Dodge-Kafka KL, Kapiloff MS. The mAKAP signaling complex: integration of cAMP, calcium, and MAP kinase signaling pathways. Eur J Cell Biol 2006;85:593-602
   PubMed Web of Science ®Google Scholar
• Francis SH, Corbin JD. Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci 1999;36:275-328
   PubMed Web of Science ®Google Scholar
• Trewhella J. Protein kinase A targeting and activation as seen by small-angle solution scattering. Eur J Cell Biol 2006;85:655-62
   PubMed Web of Science ®Google Scholar
• Zaccolo M. Phosphodiesterases and compartmentalized cAMP signalling in the heart. Eur J Cell Biol 2006;85:693-7
   PubMed Web of Science ®Google Scholar
• Halpin DM. ABCD of the phosphodiesterase family: interaction and differential activity in COPD. Int J Chron Obstruct Pulmon Dis 2008;3:543-61
   PubMedGoogle Scholar
• Han P, Sonati P, Rubin C, Michaeli T. PDE7A1, a cAMP-specific phosphodiesterase, inhibits cAMP-dependent protein kinase by a direct interaction with C. J Biol Chem 2006;281:15050-7
   PubMed Web of Science ®Google Scholar
• Kaupp UB, Seifert R. Cyclic nucleotide-gated ion channels. Physiol Rev 2002;82(3):769-824
   PubMed Web of Science ®Google Scholar
• Breckler M, Berthouze M, Laurent AC, et al. Rap-linked cAMP signaling Epac proteins: compartmentation, functioning and disease implications. Cell Signal 2011;23(8):1257-66
   PubMed Web of Science ®Google Scholar
• Rangarajan S, Enserink JM, Kuiperij HB, et al. Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the beta 2-adrenergic receptor. J Cell Biol 2003;160(4):487-93
   PubMed Web of Science ®Google Scholar
• Kooistra MR, Corada M, Dejana E, Bos JL. Epac1 regulates integrity of endothelial cell junctions through VE-cadherin. FEBS Lett 2005;579(22):4966-72
   PubMed Web of Science ®Google Scholar
• Li J, O'Connor KL, Cheng X, et al. Cyclic adenosine 5'-monophosphate-stimulated neurotensin secretion is mediated through Rap1 downstream of both Epac and protein kinase A signaling pathways. Mol Endocrinol 2007;21(1):159-71
   PubMed Web of Science ®Google Scholar
• Monaghan TK, Mackenzie CJ, Plevin R, Lutz EM. PACAP-38 induces neuronal differentiation of human SH-SY5Y neuroblastoma cells via cAMP-mediated activation of ERK and p38 MAP kinases. J Neurochem 2008;104(1):74-88
   PubMed Web of Science ®Google Scholar
• Ostroveanu A, van der Zee EA, Eisel UL, et al. Exchange protein activated by cyclic AMP 2 (Epac2) plays a specific and time-limited role in memory retrieval. Hippocampus 2010;20(9):1018-26
   PubMed Web of Science ®Google Scholar
• Sands WA, Woolson HD, Milne GR, et al. Exchange protein activated bycyclic AMP (Epac)-mediated induction of suppressor of cytokine signaling 3 (SOCS-3) in vascular endothelial cells. Hippocampus 2010;20(9):1018-26
   PubMedGoogle Scholar
• Borland G, Smith BO, Yarwood SJ. EPAC proteins transduce diverse cellular actions of cAMP. Br J Pharmacol 2009;158(1):70-86
   PubMed Web of Science ®Google Scholar
• Laurent AC, Breckler M, Berthouze M, Lezoualc'h F. Role of Epac in brain and heart. Biochem Soc Trans 2012;40(1):51-7
   PubMedGoogle Scholar
• Mosenden R, Taskén K. Cyclic AMP-mediated immune regulation–overview of mechanisms of action in T cells. Cell Signal 2011;23(6):1009-16
   PubMed Web of Science ®Google Scholar
• Gerlo S, Verdood P, Hooghe-Peters EL, Kooijman R. Multiple cAMP-induced signaling cascades regulate prolactin expression in T cells. Cell Mol Life Sci 2006;63(1):92-9
   PubMed Web of Science ®Google Scholar
• Eigler A, Siegmund B, Emmerich U, et al. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol 1998;63:101-7
   PubMed Web of Science ®Google Scholar
• Bryn T, Mahic M, Enserink JM, et al. The cyclic AMP-Epac1-Rap1 pathway is dissociated from regulation of effector functions in monocytes but acquires immunoregulatory function in mature macrophages. J Immunol 2006;176:7361-70
   PubMed Web of Science ®Google Scholar
• Levy FO, Rasmussen AM, Taskén K, et al. Cyclic AMP-dependent protein kinase (cAK) in human B cells: co-localization of type I cAK (RI alpha 2 C2) with the antigen receptor during anti-immunoglobulin-induced B cell activation. Eur J Immunol 1996;26(6):1290-6
   PubMed Web of Science ®Google Scholar
• Tiwari S, Felekkis K, Moon EY, et al. Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis. Blood 2004;103(7):2661-7
   PubMed Web of Science ®Google Scholar
• Murray AJ, Shewan DA. Epac mediates cyclic AMP-dependent axon growth, guidance and regeneration. Mol Cell Neurosci 2008;38(4):578-88
   PubMed Web of Science ®Google Scholar
• Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 2000;47:63-83
   PubMed Web of Science ®Google Scholar
• Essayan DM. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem Pharmacol 1999;57:965-73
   PubMed Web of Science ®Google Scholar
• Gil C, Campillo NE, Perez DI, Martinez A. PDE7 inhibitors as new drugs for neurological and inflammatory disorders. Expert Opin Ther Patents 2008;18(10):1127-39
   Web of Science ®Google Scholar
• Giembycz MA, Smith SJ. Phosphodiesterase 7 (PDE7) as a therapeutic target. Drugs Future 2006;31(3):207-29
   Web of Science ®Google Scholar
• Sasaki T, Kotera J, Kenji Omori K. Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP dependent protein kinase/cyclic AMP-response element binding protein pathway in primary striatal neurons. J Neurochem 2004;89:474-83
   PubMed Web of Science ®Google Scholar
• Walikonis RS, Poduslo JF. Activity of Cyclic AMP Phosphodiesterases and adenylyl cyclase in peripheral nerve after crush and permanent transection injuries. J Biol Chem 1998;273(15):9070-7
   PubMed Web of Science ®Google Scholar
• Iancu R, Ramamurthy G, Warrier S, et al. Cytoplasmic cAMP concentrations in intact cardiac myocytes. Am J Physiol Cell Physiol 2008;295:C414-22
   PubMed Web of Science ®Google Scholar
• Rezvanfar MA, Rahimi HR, Abdollahi M. ADMET considerations for phosphodiesterase-5 inhibitors. Expert Opin Drug Metab Toxicol 2012;8(10):1231-45
   PubMed Web of Science ®Google Scholar
• Daga PR, Doerksen RJ. Stereoelectronic properties of spiroquinazolinones in differential PDE7 inhibitory activity. J Comput Chem 2008;29:1945-54
   PubMed Web of Science ®Google Scholar
• Zhang KY, Card GL, Suzuki Y, et al. A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell 2004;15:279-86
   PubMed Web of Science ®Google Scholar
• Jeon YH, Heo YS, Kim CM, et al. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci 2005;62:1198-220
   PubMed Web of Science ®Google Scholar
• Card GL, England BP, Suzuki Y, et al. Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure 2004;12:2233-47
   PubMed Web of Science ®Google Scholar
• Jin SL, Swinnen JV, Conti M. Characterization of the structure of a low Km, rolipram-sensitive cAMP phosphodiesterase. Mapping of the catalytic domain. J Biol Chem 1992;267:18929-39
   PubMed Web of Science ®Google Scholar
• Wang H, Liu Y, Chen Y, et al. Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7. J Biol Chem 2005;280:30949-55
   PubMed Web of Science ®Google Scholar
• Fortin M, D'Anjou H, Higgins ME, et al. A multi-target antisense approach against PDE4 and PDE7 reduces smokeinduced lung inflammation in mice. Respir Res 2009;10:39
   PubMedGoogle Scholar
• Li L, Yee C, Beavo JA. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 1999;283(5403):848-51
   PubMed Web of Science ®Google Scholar
• Yang G, McIntyre KW, Townsend RM, et al. Phosphodiesterase 7A-deficient mice have functional T cells. J Immunol 2003;171:6414-20
   PubMed Web of Science ®Google Scholar
• Smith SJ, Cieslinski LB, Newton R, et al. Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol 2004;66:1679-89
   PubMed Web of Science ®Google Scholar
• Kadoshima-Yamaoka K, Murakawa M, Goto M, et al. ASB16165, a novel inhibitor for phosphodiesterase 7A (PDE7A), suppresses IL-12-induced IFN-gamma production by mouse activated T lymphocytes. Immunol Lett 2009;122(2):193-7
   PubMed Web of Science ®Google Scholar
• Goto M, Murakawa M, Kadoshima-Yamaoka K. Phosphodiesterase 7A inhibitor ASB16165 suppresses proliferation and cytokine production of NKT cells. Cell Immunol 2009;258(2):147-51
   PubMed Web of Science ®Google Scholar
• Kadoshima-Yamaoka K, Murakawa M, Goto M, et al. Effect of phosphodiesterase 7 inhibitor ASB16165 on development and function of cytotoxic T lymphocyte. Int Immunopharmacol 2009;9(1):97-102
   PubMed Web of Science ®Google Scholar
• Murakawa M, Yamaoka K, Tanaka Y, Fukuda Y. Involvement of tumor necrosis factor (TNF)-alpha in phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin edema in mice. Biochem Pharmacol 2006;71(9):1331-6
   PubMed Web of Science ®Google Scholar
• Kadoshima-Yamaoka K, Goto M, Murakawa M, et al. ASB16165, a phosphodiesterase 7A inhibitor, reduces cutaneous TNF-alpha level and ameliorates skin edema in phorbol ester 12-O-tetradecanoylphorbol-13-acetate-induced skin inflammation model in mice. Eur J Pharmacol 2009;613(1-3):163-6
   PubMed Web of Science ®Google Scholar
• Paterniti I, Mazzon E, Gil C, et al. PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury. PLoS One 2011;6(1):e15937
   PubMedGoogle Scholar
• Redondo M, Brea J, Perez DI, et al. Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds. J Med Chem 2012;55:3274-84
   PubMed Web of Science ®Google Scholar
• Zhang L, Murray F, Rassenti LZ, et al. Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia. Int J Cancer 2011;129(5):1162-9
   PubMed Web of Science ®Google Scholar
• Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013;110(9):3507-12
   PubMed Web of Science ®Google Scholar
• Martinez A, Castro A, Gil C, et al. Benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides: first phosphodiesterase 7 inhibitors. J Med Chem 2000;43:683-9
   PubMed Web of Science ®Google Scholar
• Castro A, Abasolo MI, Gil C, et al. CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-alpha]thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors. Eur J Med Chem 2001;36:333-8
   PubMed Web of Science ®Google Scholar
• Barnes MJ, Cooper N, Davenport RJ, et al. Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors. Bioorg Med Chem Lett 2001;11:1081-3
   PubMed Web of Science ®Google Scholar
• Lorthiois E, Bernardelli P, Vergne F, et al. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1. Bioorg Med Chem Lett 2004;14:4623-6
   PubMed Web of Science ®Google Scholar
• Bernardelli P, Lorthiois E, Vergne F, et al. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: optimization of 5,8-disubstituted derivatives. Bioorg Med Chem Lett 2004;14:4627-31
   PubMed Web of Science ®Google Scholar
• Pitts WJ, Vaccaro W, Huynh T, et al. Identification of purine inhibitors of phosphodiesterase 7 (PDE7). Bioorg Med Chem Lett 2004;14:2955-8
   PubMed Web of Science ®Google Scholar
• Vergne F, Bernardelli P, Lorthiois E, et al. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies. Bioorg Med Chem Lett 2004;14:4607-13
   PubMed Web of Science ®Google Scholar
• Vergne F, Bernardelli P, Lorthiois E, et al. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives. Bioorg Med Chem Lett 2004;14:4615-21
   PubMed Web of Science ®Google Scholar
• Kempson J, Pitts WJ, Barbosa J, et al. Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships. Bioorg Med Chem Lett 2005;15:1829-33
   PubMed Web of Science ®Google Scholar
• Castro A, Jerez MJ, Gil C, et al. CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. Eur J Med Chem 2008;43:1349-59
   PubMed Web of Science ®Google Scholar
• Reddy AS, Pati SP, Kumar PP, et al. Virtual screening in drug discovery - a computational perspective. Curr Protein Pept Sci 2007;8:329-51
   PubMed Web of Science ®Google Scholar
• Guo J, Watson A, Kempson J, et al. Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation. Bioorg Med Chem Lett 2009;19:1935-8
   PubMed Web of Science ®Google Scholar
• Castano T, Wang H, Campillo NE, et al. Synthesis, structural analysis, and biological evaluation of thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors. Chem Med Chem 2009;4:866-76
   Google Scholar
• Alaamery MA, Wyman AR, Ivey FD, et al. New classes of PDE7 inhibitors identified by a fission yeast-based HTS. J Biomol Screen 2010;15(4):359-67
   PubMed Web of Science ®Google Scholar
• Gewald R, Rueger C, Grunwald C, et al. Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors. Bioorg Med Chem Lett 2011;21:6652-6
   PubMed Web of Science ®Google Scholar
• Banerjee A, Yadav PS, Bajpai M, et al. Isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors: SAR and pharmacokinetic evaluation. Bioorg Med Chem Lett 2012;22:3223-8
   PubMed Web of Science ®Google Scholar
• Banerjee A, Patil S, Pawar MY, et al. Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model. Bioorg Med Chem Lett 2012;22:6286-91
   PubMed Web of Science ®Google Scholar
• Redondo M, Zarruk JG, Ceballos P, et al. Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. Eur J Med Chem 2012;47:175-85
   PubMed Web of Science ®Google Scholar